Boston Scientific is buying Cryterion Medical, owner of an invention that uses a burst of cold to the heart to treat atrial fibrillation, for $200 million. (Evan Ramstad — Bloomberg News/The ...

Boston Scientific Corp. (BSX) on Thursday said it agreed to buy the roughly 65% of Cryterion Medical Inc. it doesn’t already own for $202 million in cash. Cryterion is developing a single-shot ...

Although Cryterion’s technology hasn’t been approved for use in any country, initial clinical trials have shown promise, according to Keegan Harper, president and CEO of Cryterion Medical.

Boston Scientific is acquiring Cryterion Medical, a company the medical device giant has invested in since its launch in 2016, by buying up the remaining 65% stake for $202 million upfront as Bosto ...

Cryterion Medical is a privately held medical device manufacturer developing a single-shot cryoablation platform to treat atrial fibrillation, which is an irregular rapid heart beat usually caused ...

Boston Scientific expects the transaction to be immaterial on an adjusted earnings per share basis through 2020, and accretive thereafter. On a GAAP basis for 2019 and subsequent years, the ...

MARLBOROUGH, Mass., July 5, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced a definitive agreement to acquire Cryterion Medical, Inc., a privately-held company ...

Boston Scientific Corp. has inked an agreement to acquire the rest of Cryterion Medical Inc. it does not own for $202 million in up-front cash. The attraction of Cryterion, of Carlsbad, Calif., is the ...

Cryterion Medical is developing a treatment for atrial fibrillation, or irregular heartbeat. Boston Scientific has been an investor in the company since it was launched in 2016.

Boston Scientific CorporationBSX recently announced the acquisition of Cryterion Medical, Inc. - a privately-held developer of a single-shot cryoablation platform for the treatment of atrial ...